Cited 3 times in
A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 노성훈 | - |
dc.contributor.author | 노재경 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 신상준 | - |
dc.contributor.author | 안중배 | - |
dc.contributor.author | 임종근 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 정희철 | - |
dc.date.accessioned | 2015-04-23T16:28:14Z | - |
dc.date.available | 2015-04-23T16:28:14Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0277-3732 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/100641 | - |
dc.description.abstract | BACKGROUND: There is no universally confirmed standard chemotherapeutic regimen for advanced gastric cancer (AGC). The aim of this study was to investigate the efficacy and safety of combined biweekly irinotecan and monthly cisplatin treatments of patients with AGC. The primary end point was progression-free survival. MATERIAL AND METHODS: AGC patients with or without measurable lesions received 70 mg/m2 irinotecan on days 1 and 15, and 80 mg/m2 cisplatin on day 1 every 4 weeks. RESULTS: Of 40 enrolled patients, 21 patients had measurable disease. With a median follow-up duration of 35 weeks, the median progression-free survival and overall survival were 2.2 months and 8.0 months, respectively. The progression-free survival rate at 6 months was 30.0%. The most common adverse event of grade 3 to 4 was neutropenia (32.5%). Grade 3 diarrhea was observed in 2 patients (5.0%). There was no treatment-related death. CONCLUSION: Current combined biweekly irinotecan and monthly cisplatin treatment did not show activity comparable with other active regimens in AGC. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 56~60 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/drug therapy* | - |
dc.subject.MESH | Adenocarcinoma/secondary | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Camptothecin/administration & dosage | - |
dc.subject.MESH | Camptothecin/analogs & derivatives | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymphatic Metastasis | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local/drug therapy* | - |
dc.subject.MESH | Neoplasm Recurrence, Local/pathology | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy* | - |
dc.subject.MESH | Stomach Neoplasms/pathology | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Chong Kun Im | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Hei-Cheul Jeung | - |
dc.contributor.googleauthor | Joong Bae Ahn | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Sung Hoon Noh | - |
dc.contributor.googleauthor | Jae Kyung Roh | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.identifier.doi | 10.1097/COC.0b013e31819fe216 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01281 | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A03402 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A03794 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00075 | - |
dc.identifier.eissn | 1537-453X | - |
dc.identifier.pmid | 19730355 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00000421-201002000-00011&LSLINK=80&D=ovft | - |
dc.subject.keyword | irinotecan | - |
dc.subject.keyword | cisplatin | - |
dc.subject.keyword | advanced gastric cancer | - |
dc.contributor.alternativeName | Noh, Sung Hoon | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.alternativeName | Ahn, Joong Bae | - |
dc.contributor.alternativeName | Im, Chong Kun | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Noh, Sung Hoon | - |
dc.contributor.affiliatedAuthor | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Ahn, Joong Bae | - |
dc.contributor.affiliatedAuthor | Im, Chong Kun | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.citation.volume | 33 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 56 | - |
dc.citation.endPage | 60 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, Vol.33(1) : 56-60, 2010 | - |
dc.identifier.rimsid | 37720 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.